An integrative Bayesian network approach to highlight key drivers in systemic lupus erythematosus.
BNrich
Cross-platform normalization
Mixture model
SLE
Signaling pathways
Systems biology
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
23 06 2020
23 06 2020
Historique:
received:
20
01
2020
accepted:
05
06
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
22
6
2021
Statut:
epublish
Résumé
A comprehensive intuition of the systemic lupus erythematosus (SLE), as a complex and multifactorial disease, is a biological challenge. Dealing with this challenge needs employing sophisticated bioinformatics algorithms to discover the unknown aspects. This study aimed to underscore key molecular characteristics of SLE pathogenesis, which may serve as effective targets for therapeutic intervention. In the present study, the human peripheral blood mononuclear cell (PBMC) microarray datasets (n = 6), generated by three platforms, which included SLE patients (n = 220) and healthy control samples (n = 135) were collected. Across each platform, we integrated the datasets by cross-platform normalization (CPN). Subsequently, through BNrich method, the structures of Bayesian networks (BNs) were extracted from KEGG-indexed SLE, TCR, and BCR signaling pathways; the values of the node (gene) and edge (intergenic relationships) parameters were estimated within each integrated datasets. Parameters with the FDR < 0.05 were considered significant. Finally, a mixture model was performed to decipher the signaling pathway alterations in the SLE patients compared to healthy controls. In the SLE signaling pathway, we identified the dysregulation of several nodes involved in the (1) clearance mechanism (SSB, MACROH2A2, TRIM21, H2AX, and C1Q gene family), (2) autoantigen presentation by MHCII (HLA gene family, CD80, IL10, TNF, and CD86), and (3) end-organ damage (FCGR1A, ELANE, and FCGR2A). As a remarkable finding, we demonstrated significant perturbation in CD80 and CD86 to CD28, CD40LG to CD40, C1QA and C1R to C2, and C1S to C4A edges. Moreover, we not only replicated previous studies regarding alterations of subnetworks involved in TCR and BCR signaling pathways (PI3K/AKT, MAPK, VAV gene family, AP-1 transcription factor) but also distinguished several significant edges between genes (PPP3 to NFATC gene families). Our findings unprecedentedly showed that different parameter values assign to the same node based on the pathway topology (the PIK3CB parameter values were 1.7 in TCR vs - 0.5 in BCR signaling pathway). Applying the BNrich as a hybridized network construction method, we highlight under-appreciated systemic alterations of SLE, TCR, and BCR signaling pathways in SLE. Consequently, having such a systems biology approach opens new insights into the context of multifactorial disorders.
Sections du résumé
BACKGROUND
A comprehensive intuition of the systemic lupus erythematosus (SLE), as a complex and multifactorial disease, is a biological challenge. Dealing with this challenge needs employing sophisticated bioinformatics algorithms to discover the unknown aspects. This study aimed to underscore key molecular characteristics of SLE pathogenesis, which may serve as effective targets for therapeutic intervention.
METHODS
In the present study, the human peripheral blood mononuclear cell (PBMC) microarray datasets (n = 6), generated by three platforms, which included SLE patients (n = 220) and healthy control samples (n = 135) were collected. Across each platform, we integrated the datasets by cross-platform normalization (CPN). Subsequently, through BNrich method, the structures of Bayesian networks (BNs) were extracted from KEGG-indexed SLE, TCR, and BCR signaling pathways; the values of the node (gene) and edge (intergenic relationships) parameters were estimated within each integrated datasets. Parameters with the FDR < 0.05 were considered significant. Finally, a mixture model was performed to decipher the signaling pathway alterations in the SLE patients compared to healthy controls.
RESULTS
In the SLE signaling pathway, we identified the dysregulation of several nodes involved in the (1) clearance mechanism (SSB, MACROH2A2, TRIM21, H2AX, and C1Q gene family), (2) autoantigen presentation by MHCII (HLA gene family, CD80, IL10, TNF, and CD86), and (3) end-organ damage (FCGR1A, ELANE, and FCGR2A). As a remarkable finding, we demonstrated significant perturbation in CD80 and CD86 to CD28, CD40LG to CD40, C1QA and C1R to C2, and C1S to C4A edges. Moreover, we not only replicated previous studies regarding alterations of subnetworks involved in TCR and BCR signaling pathways (PI3K/AKT, MAPK, VAV gene family, AP-1 transcription factor) but also distinguished several significant edges between genes (PPP3 to NFATC gene families). Our findings unprecedentedly showed that different parameter values assign to the same node based on the pathway topology (the PIK3CB parameter values were 1.7 in TCR vs - 0.5 in BCR signaling pathway).
CONCLUSIONS
Applying the BNrich as a hybridized network construction method, we highlight under-appreciated systemic alterations of SLE, TCR, and BCR signaling pathways in SLE. Consequently, having such a systems biology approach opens new insights into the context of multifactorial disorders.
Identifiants
pubmed: 32576231
doi: 10.1186/s13075-020-02239-3
pii: 10.1186/s13075-020-02239-3
pmc: PMC7310461
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
156Références
J Exp Med. 2009 Aug 3;206(8):1661-71
pubmed: 19635858
Immunity. 2014 Jun 19;40(6):949-60
pubmed: 24909887
ISRN Bioinform. 2014 Jan 12;2014:345106
pubmed: 25937953
Int J Rheum Dis. 2018 Oct;21(10):1831-1837
pubmed: 28730681
Hum Genomics Proteomics. 2009 Jan 12;2009:
pubmed: 20948564
Genes Immun. 2013 Apr;14(3):133-46
pubmed: 23446742
Nat Rev Rheumatol. 2016 Nov 22;12(12):716-730
pubmed: 27872476
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
J Immunol. 2019 Jun 1;202(11):3161-3172
pubmed: 31019063
Arthritis Res Ther. 2016 Jul 13;18:162
pubmed: 27412348
Anal Chim Acta. 2014 Aug 1;838:1-12
pubmed: 25064237
BMC Med Genomics. 2019 Jan 9;12(1):4
pubmed: 30626389
Immunogenetics. 2019 Apr;71(4):283-297
pubmed: 30671674
Adv Drug Deliv Rev. 2019 Feb 15;141:92-103
pubmed: 30552917
Front Immunol. 2018 May 17;9:1088
pubmed: 29868033
Arthritis Res Ther. 2011 Apr 15;13(2):R63
pubmed: 21496236
Arthritis Res Ther. 2011 Jul 06;13(4):228
pubmed: 21745419
Sci Rep. 2018 May 3;8(1):6951
pubmed: 29725024
PLoS One. 2018 Apr 4;13(4):e0194844
pubmed: 29617451
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Arthritis Res Ther. 2009;11(1):R1
pubmed: 19121222
Front Immunol. 2020 Feb 07;11:98
pubmed: 32117252
Cost Eff Resour Alloc. 2015 May 06;13:9
pubmed: 26019689
DNA Repair (Amst). 2017 Aug;56:174-182
pubmed: 28623091
Microarrays (Basel). 2015 Aug 21;4(3):389-406
pubmed: 27600230
Front Immunol. 2016 Feb 24;7:55
pubmed: 26941740
Science. 2003 Sep 5;301(5638):1374-7
pubmed: 12920303
Rheumatology (Oxford). 2020 Jan 1;59(1):90-98
pubmed: 31236574
JCI Insight. 2020 Feb 27;5(4):
pubmed: 31971918
Gac Med Mex. 2018;154(1):74-79
pubmed: 29420529
Nat Commun. 2019 May 17;10(1):2201
pubmed: 31101814
Science. 2015 Oct 23;350(6259):455-9
pubmed: 26382853
Int J Genomics. 2016;2016:7862962
pubmed: 27656648
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Clin Rheumatol. 2020 Feb;39(2):425-434
pubmed: 31673979
Semin Arthritis Rheum. 2020 Apr;50(2):314-320
pubmed: 31796213
Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i55-i66
pubmed: 28375453
Cancer Res. 2017 Apr 1;77(7):1575-1585
pubmed: 28087598
Lupus Sci Med. 2015 Mar 28;2(1):e000080
pubmed: 25861459
Breast Cancer Res Treat. 2018 Nov;172(2):469-485
pubmed: 30128822
Biomed Res Int. 2014;2014:651751
pubmed: 25101291
Radiother Oncol. 2017 Apr;123(1):85-92
pubmed: 28237401
J Exp Med. 2010 Jul 5;207(7):1485-500
pubmed: 20566717
Mod Rheumatol. 2018 Nov;28(6):993-1003
pubmed: 29385873
Int J Mol Sci. 2019 Nov 29;20(23):
pubmed: 31795353
Nat Rev Rheumatol. 2020 Feb;16(2):100-112
pubmed: 31949287
Roum Arch Microbiol Immunol. 2009 Apr-Jun;68(2):69-79
pubmed: 20361524
Brain Behav Immun. 2015 May;46:96-103
pubmed: 25582808
Arthritis Rheum. 2008 Jan;58(1):15-25
pubmed: 18163481
Arthritis Res Ther. 2018 May 30;20(1):100
pubmed: 29848360
PLoS One. 2019 Dec 2;14(12):e0225651
pubmed: 31790472
Arthritis Rheumatol. 2018 Dec;70(12):2025-2035
pubmed: 29938934
Bioinformatics. 2004 Dec 12;20(18):3594-603
pubmed: 15284094
PLoS Genet. 2015 Jun 09;11(6):e1005248
pubmed: 26057447
Int J Mol Sci. 2019 Nov 13;20(22):
pubmed: 31766160
Int J Health Sci (Qassim). 2018 Jan-Feb;12(1):21-27
pubmed: 29623013